打开APP

葛兰素史克被调查——阿斯利康增加中国投资

  1. 葛兰素史克
  2. 行贿案
  3. 阿斯利康

来源:生物谷 2013-09-09 13:34

2013年8月1日讯 /生物谷BIOON/ --阿斯利康(AstraZeneca)将增加在中国的投资,该公司第二季度在中国的销售增长21%,尽管中国目前正在加大对医疗保健行业不法行为的打击力度。

2013年8月1日讯 /生物谷BIOON/ --阿斯利康(AstraZeneca)将增加在中国的投资,该公司第二季度在中国的销售增长21%,尽管中国目前正在加大对医疗保健行业不法行为的打击力度。

阿斯利康(AstraZeneca)CEO 索里奥特(Pascal Soriot)在7月31日电话会议上讨论盈余时称,尽管药价已经下降,但随着中国医疗覆盖面的不断扩大,该公司已经在中国增加了更多的销售人员。

目前,中国当局正在调查阿斯利康的竞争对手葛兰素史克(GSK)有关30亿人民币(约合4.89亿美元)虚假差旅费及会议费用指控。赛诺菲(Sanofi)和礼来(LLY)表示,昨天已接受中国监管机构到访。目前,阿斯利康有一名销售代表由于一个个案仍被关押在上海。

Soriot称:“我们在中国的机构,非常注重以正确的方式在中国开展业务。我们的重点是研究和开发新药来帮助患者。中国有12亿人口,所以我们非常专注于在该国的业务增长。阿斯利康没有理由相信此次销售代表调查事件将会扩大,而且目前还没有受到任何指控。与该案件相关的另外2名雇员已被立即释放。”(生物谷Bioon.com)

英文原文:AstraZeneca Ups China Investment as Rivals Face Scrutiny

By Bloomberg News - 2013-08-01T16:12:33Z

AstraZeneca Plc (AZN) is increasing its investment in China, where sales rose 21 percent in the second quarter, as the country continues its crackdown on malfeasance in the health-care industry.

The U.K.’s second-biggest drugmaker has added more sales people in China as the country’s medical coverage expands, even as prices have declined, AstraZeneca Chief Executive Officer Pascal Soriot told journalists yesterday on a conference call to discuss earnings.

Chinese authorities are investigating AstraZeneca’s larger U.K. rival, GlaxoSmithKline Plc (GSK), over allegations of 3 billion yuan ($489 million) in spurious travel and meeting expenses. Sanofi (SAN) and Eli Lilly & Co. (LLY) said yesterday they had received visits from Chinese regulators. An AstraZeneca sales representative remains detained in Shanghai as police examine an individual case, Soriot said.

“Our organization in China is very focused on doing business in China the right way,” Soriot said. “Our focus is on science and developing medicines that help patients. There are 1.2 billion patients in China, so we are very focused on growing in China.”

AstraZeneca has no reason to believe the investigation of the sales representative will expand, and no charges have been brought, he said. Two other employees were questioned in relation to the case and were immediately released, Soriot said.

Closer Checks

The regional manager for China and the company’s compliance organization gives Soriot regular updates, the CEO said. The company does regular compliance checks, and was conducting one as the Glaxo investigation became public, he said.

“We suddenly are looking at routine processes more closely than we would have otherwise,” Soriot said. “We’re not complacent at all.”

Johnson & Johnson (JNJ), the world’s biggest maker of health-care products, was fined by Chinese authorities for monopolistic practices.

Two of New Brunswick, New Jersey-based J&J’s units were ordered to compensate 530,000 yuan ($86,500) to a distributor after a court in Shanghai ruled yesterday that their setting of minimum resale prices constituted monopolistic conduct, according to a report posted to chinacourt.org, a website controlled by the nation’s Supreme Court.

J&J Ruling

The ruling resolves a case brought by J&J in 2008 against a distributor that the company said was selling products outside of its covered sales area. While J&J won a lower court ruling, the distributor appealed and countersued, charging the U.S. company was engaging in monopolistic behavior, said Ernie Knewitz, a spokesman for Johnson & Johnson.

“While we are disappointed with the ruling by the Higher People’s Court of Shanghai, we are pleased to have put this matter behind us, and look forward to continuing to provide our high quality products and services to health-care institutions and patients in China,” Knewitz said in a statement.

Chinese authorities have accused Glaxo of economic crimes amounting to 3 billion yuan in spurious travel and meeting expenses as well as trade in sexual favors undertaken to boost sales.

Regulators will “severely crack down” on fake medications, forged documents and bribery, the China Food and Drug Administration said last month.

Glaxo’s head of emerging markets, Abbas Hussain, said last month after meeting with government officials in Beijing that some employees may have broken China’s laws.

Local Agencies

In China, every province and city has local agencies that regulate commercial activity. These units, formally known as the Administration for Industry and Commerce, hold broad powers to investigate possible malfeasance, seize evidence without a warrant and impose financial penalties, according to a note from consulting firm Control Risks.

Sanofi said yesterday one of its regional offices was visited by authorities from the Shenyang Administration for Industry and Commerce. The Paris-based company didn’t know the purpose of the inspection, Chief Executive Officer Chris Viehbacher said on a call with reporters, and its China headquarters in Shanghai haven’t been checked.

Lilly was also visited by Shenyang authorities in a review “early this year,” the company said in an e-mailed response to questions, without elaborating on the date. The Indianapolis-based company said it hadn’t received any notice of the results of the investigation.

In China, Lilly is “one of the first companies in the industry to enforce compliance in a strict manner,” according to the company. “Lilly has not and is not being investigated by the Chinese Public Security Bureau,” its Beijing-based spokeswoman Connie Li said in the e-mailed statement.

葛兰素史克行贿风波相关新闻阅读:

英媒:葛兰素史克考虑退出中国 不想承担200亿罚单http://www.bioon.com/industry/enterprisenews/581601.shtml

葛兰素史克回应:“千万公关费”是业务问题http://www.bioon.com/industry/enterprisenews/581460.shtml

葛兰素史克高层默许在中国行贿 年公关费上千万http://www.bioon.com/industry/enterprisenews/581359.shtml

中国针对葛兰素史克等药企反腐对医药市场增长产生很大影响http://www.bioon.com/industry/mdnews/581174.shtml

葛兰素史克风波新进展:年送大客户近千万 高管收受康辉贿赂http://www.bioon.com/industry/mdnews/581118.shtml

2013上半年美国FDA批准的新药名单 13种新药葛兰素史克(GSK)占三种http://www.bioon.com/industry/internation/580721.shtml

葛兰素史克HIV新药Tivicay获FDA批准http://www.bioon.com/industry/drug/579460.shtml

葛兰素史克案发酵:扬子江等国企会议费更惊人http://www.bioon.com/industry/mdnews/579297.shtml

葛兰素史克糖尿病新药被FDA延迟审批http://www.bioon.com/biopharm/578659.shtml

葛兰素史克否认因“行贿门”裁员百人http://www.bioon.com/industry/mdnews/578223.shtml

葛兰素史克将更换中国高管 在华团队大换血http://www.bioon.com/industry/mdnews/577957.shtml

葛兰素史克中国业务至少18人被拘http://www.bioon.com/industry/mdnews/577947.shtml

葛兰素史克涉贿案引发药品降价期待http://www.bioon.com/industry/mdnews/577809.shtml

葛兰素史克中国区运营几乎瘫痪 研发中心涉造假http://www.bioon.com/industry/mdnews/577804.shtml

葛兰素史克研发再曝黑幕 在华违规进行人体试验http://www.bioon.com/industry/enterprisenews/577802.shtml

葛兰素史克:医生最欢迎吃不死治不好高价药http://www.bioon.com/industry/mdnews/577800.shtml

葛兰素史克称对贿赂案感到羞耻 对涉案员工深感失望http://www.bioon.com/industry/enterprisenews/577693.shtml

葛兰素史克:二季度中国销售额20亿人民币 99.9%的员工都是正派的http://www.bioon.com/industry/enterprisenews/577692.shtml

路透社:葛兰素史克CEO本周三将在季报中解释中国行贿案http://www.bioon.com/industry/internation/577231.shtml

公安部约见葛兰素史克高层 后者承诺降药价http://www.bioon.com/industry/mdnews/577209.shtml

葛兰素史克该成为“落水狗”吗?http://www.bioon.com/z/zmb/column/201307/577006.shtml

葛兰素史克高管细数关系单位 药监总局发改委等被点名http://www.bioon.com/industry/mdnews/576938.shtml

英金融时报:葛兰素史克派人赴华展开内部调查http://www.bioon.com/industry/enterprisenews/576927.shtml

英金融时报:葛兰素史克案凸显中国医疗体制扭曲http://www.bioon.com/industry/mdnews/576925.shtml

葛兰素史克英国籍中国财务总监被限制离境http://www.bioon.com/industry/mdnews/576888.shtml

外媒:葛兰素史克贿赂丑闻涉700家公司5亿美元http://www.bioon.com/industry/mdnews/576734.shtml

关于葛兰素史克中国区行贿的十个“为什么”http://www.bioon.com/industry/mdnews/576736.shtml

葛兰素史克就涉贿道歉:支持中国政府根除腐败http://www.bioon.com/industry/mdnews/576696.shtml

葛兰素史克深陷贿赂丑闻 医药行业潜规则浮出水面http://www.bioon.com/industry/mdnews/576622.shtml

跨国药企葛兰素史克在华行贿推高药价内幕披露http://www.bioon.com/industry/enterprisenews/576563.shtml

葛兰素史克贿赂案调查:旅行社成药企黑金池http://www.bioon.com/industry/mdnews/576558.shtml

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->